Key Capital Corporation: Key Capital COVID-19 Oral Pill Vaccine Records 90% Reduction in Virus Infectivity in Early Study
NEW YORK, NY / ACCESSWIRE / January 18, 2021 / KEY CAPITAL CORPORATION (OTC PINK:KCPC)
is pleased to
advise that current independent laboratory testing of its partnered Immunitor COVID-19 patented oral pill vaccine in an ongoing university study is providing promising early support for safety and efficacy of the vaccine.
The preliminary tests conducted by a leading Asian research institute have shown safety and a 90% reduction on virus infectivity in mammalian cells following exposure to the active vaccine. This laboratory testing highlights the vaccine methodology and ability to inactivate and/or prevent viral infection and its potential for oral mucosal administration.
Key Capital COVID-19 Oral Pill Vaccine Records 90% Reduction in Virus Infectivity in Early Study tennesseedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tennesseedaily.com Daily Mail and Mail on Sunday newspapers.